Related Experiment Videos
Photodynamic therapy using m-tetra(hydroxyphenyl) chlorin. An animal model
L A Lofgren1, A M Ronn, A L Abramson
1Department of Otolaryngology and Communicative Disorders, Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, NY.
Archives of Otolaryngology--Head & Neck Surgery
|December 1, 1994
Summary
The photosensitizer m-tetra (hydroxyphenyl) chlorin (m-THPC) effectively treats papilloma virus-induced tumors in animal models. This study outlines a protocol for optimizing photodynamic therapy to destroy tumors while minimizing damage to healthy tissues.
Area of Science:
- Photodynamic therapy
- Oncology
- Dermatology
Background:
- Photodynamic therapy (PDT) utilizes photosensitizers and light to generate cytotoxic effects.
- m-tetra (hydroxyphenyl) chlorin (m-THPC) is a potent photosensitizer with potential therapeutic applications.
- Papillomavirus-induced tumors present a therapeutic challenge.
Purpose of the Study:
- To evaluate the efficacy of m-THPC as a photosensitizer for treating papilloma virus-induced tumors.
- To determine optimal parameters for PDT using m-THPC in preclinical models.
- To establish a protocol for minimizing normal tissue damage during PDT.
Main Methods:
- Nonrandomized control trial using rabbits and canines as model systems.
- Animals were injected with m-THPC and exposed to 652 nm light at varying intervals.
- Outcome measures included drug concentration, tissue retention, light tolerance thresholds, and tumor response.
Main Results:
- The optimal ratio of drug concentration in tumor to skin was observed 4 to 8 days post-injection.
- Damage thresholds for rabbit skin and canine laryngeal mucosa were established.
- A 75% cure rate was achieved for small papillomas using PDT with m-THPC.
Conclusions:
- m-THPC demonstrates significant efficacy in treating papilloma virus-induced tumors.
- The study provides a protocol for optimizing PDT parameters for tumor destruction with minimal normal tissue toxicity.
- This approach facilitates the development of optimal therapeutic protocols for various photosensitizers.